Here are the 10-K annual reports from Supernus, Inc. (SUPN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SUPN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SUPN filings page.
Indivior Pharmaceuticals, Inc. describes its transition to a U.S.-domiciled parent company and its core focus on treating opioid use disorder (OUD), led by long-acting injectable SUBLOCADE and sublingual SUBOXONE Film and SUBUTEX.
The company reports that the U.S. generated 85% of net revenues in 2025, driven mainly by SUBLOCADE, which delivered $856 million of 2025 global net sales versus $346 million from sublingual products. SUBLOCADE has treated more than 475,000 patients since approval and gained an FDA label expansion in 2025 enabling rapid initiation and more flexible injection sites.
Indivior highlights 2025 developments including CEO succession to Joseph Ciaffoni, inclusion in major U.S. equity indices, restructuring of R&D and Medical Affairs, and exit from several smaller Rest of World markets to concentrate on the U.S., Canada, Australia, France, and Germany. The company also outlines a pipeline featuring INDV-6001, a potential three‑month buprenorphine injection, and INDV-2000, a non‑opioid OUD candidate, both with Phase 2 studies completed in 2025 and results expected in 2026.